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Abstract
Purpose Prostate stem cell antigen (PSCA), a cell surface
glycoprotein expressed in normal human prostate and
bladder, is over-expressed in the majority of localized
prostate cancer and most bone metastases. We have
previously shown that the hu1G8 minibody, a humanized
anti-PSCA antibody fragment (single-chain Fv-CH3 dimer,
80 kDa), can localize specifically and image PSCA-
expressing xenografts at 21 h post-injection. However, the
humanization and antibody fragment reformatting decreased
its apparent affinity. Here, we sought to evaluate PET imaging
contrast with affinity matured minibodies.
Methods Yeast scFv display, involving four rounds of
selection, was used to generate the three affinity matured
antibody fragments (A2, A11, and C5) that were reformatted
into minibodies. These three affinity matured anti-PSCA
minibodies were characterized in vitro, and following radio-
labeling with 124I were evaluated in vivo for microPET
imaging of PSCA-expressing tumors.
Results The A2, A11, and C5 minibody variants all
demonstrated improved affinity compared to the parental
(P) minibody and were ranked as follows: A2>A11>C5>P.
The 124I-labeled A11 minibody demonstrated higher im-
munoreactivity than the parental minibody and also
achieved the best microPET imaging contrast in two
xenograft models, LAPC-9 (prostate cancer) and Capan-1
(pancreatic cancer), when evaluated in vivo.
Conclusion Of the affinity variant minibodies tested, the
A11 minibody that ranked second in affinity was selected
as the best immunoPET tracer to image PSCA-expressing
xenografts. This candidate is currently under development
for evaluation in a pilot clinical imaging study.
Keywords Imaging . Prostate . Cancer . PSCA .
Antibody . PET
Introduction
New imaging modalities for prostate cancer are needed for
the accurate detection, staging, and monitoring of prostate
cancer. PET imaging using 18F-FDG, although widely
embraced in oncology, frequently falls short in prostate
cancer due to low and heterogeneous uptake of the tracer;
furthermore, proximity to the bladder interferes with
imaging primary disease. More recently, metabolic tracers
have been successfully tested for prostate cancer, including
11C-choline, 11C-acetate, 18F-fluorocholine, and anti-18F-
FACBC, a synthetic leucine analog [1, 2]. Although these
tracers are able to quantify cellular processes which are
modified in prostate cancer, they are not prostate cancer
specific. Prostate cancer metastasizes primarily to lymph nodes
and bones, with bone metastases being the predominant
manifestation and major cause for mortality. Bone scintigraphy
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using 99mTc-methylene diphosphonate remains the primary
clinical imaging tool for detection of metastases; however, it is
not tumor specific. In addition, bone scans have limited utility for
monitoring response to treatment, since signal can remain long
after viable tumor is eliminated, and in many instances, a post-
treatment flare reaction can further complicate interpretation.
To generate more specific probes for prostate cancer, cell
surface markers and receptors can be targeted. One strategy
comprises radiolabeling antibodies or antibody fragments,
which recognize cell surface markers, with a radionuclide
which can be detected in vivo by single photon emission
computed tomography (immunoSPECT) or positron emission
tomography (immunoPET) [3]. Capromab pendetide, or
ProstaScint™ (Cytogen Corp., Princeton, NJ, USA), is an
111In-labeled murine anti-PSMA (prostate-specific membrane
antigen) monoclonal antibody (mAb) that was approved by
the US Food and DrugAdministration (FDA) for the detection
of recurrent local disease and lymph node metastases [4].
However, there are several limitations with this tracer
including low imaging contrast, delayed imaging, and the
induction of an immune response after the first injection [5].
Another promising cell surface target for molecular
imaging of prostate cancer is the prostate stem cell antigen
(PSCA), which is over-expressed in a majority of prostate
cancers and has low levels of expression in a very limited
number of normal tissues [6, 7]. Other than expression in
normal prostate, the most noticeable PSCA expression
detected by immunohistochemistry was in the bladder and
neuroendocrine cells of the stomach and colon [8]. In the
same study PSCA protein was shown to be over-expressed
by a majority of localized prostate cancers and to correlate
with Gleason score, pathologic stage and androgen indepen-
dence. Furthermore, PSCA was detected in over 60% of
lymph node and liver metastases and strong PSCA staining
was observed in 87–100% of bone metastases [8, 9]. In
addition, PSCA is also highly expressed in localized bladder
and pancreatic carcinoma [10–12].
We have previously evaluated a humanized anti-PSCA
intact antibody (hu1G8) as a molecular imaging probe for
microPET imaging [13]. Hu1G8 was radiolabeled with the
positron emitter 124I (T1/2 4.2 days) and injected into SCID
mice bearing LAPC-9 xenografts. Tumors were detected by
microPET imaging, with the maximal target to background
signal obtained 1 week after injection. In an effort to
optimize PSCA-targeted prostate tumor imaging, we have
engineered several hu1G8 antibody fragments to improve
the pharmacokinetics of the immunoPET probe. One of
these engineered proteins, the hu1G8 minibody (single-chain
Fv-CH3 dimer, 80 kDa) shown in Fig. 1, demonstrated faster
blood clearance kinetics resulting in clear image contrast of
prostate cancer xenografts at 21 h [14].
The apparent affinities of the intact hu1G8 antibody and
minibody are 5 and 46 nM, respectively, which represents a
∼ninefold loss [14]. The effect of affinity on intact antibody
and antibody fragments tumor targeting is a controversial
subject. The mathematical model of intact antibody
distribution of Fujimori et al. suggests that if one considers
that a uniform repartition is desired for therapy, a lower
affinity antibody might be preferable [15]. In animal
models, a number of studies show increased delivery and/or
therapeutic efficacy of higher affinity intact antibody [16–18].
In another study intact antibodies with KD above 1 nM (3.4
and 11) have shown better tumor delivery than antibodies
with sub nM KD [19]. Tumor targeting of small antibody
fragments such as single-chain Fv (scFv, 25 kDa) or diabody
(scFv dimer, 50 kDa) has also suggested that the best tumor
targeting would be obtained at close to nanomolar affinity for
these smaller engineered antibody fragments [20, 21].
Our goal was to improve the affinity of the parental anti-
PSCA hu1G8 minibody in an effort to generate a tracer with
better PET imaging contrast. Molecular evolution associated
with yeast display is a powerful strategy for antibody affinity
maturation. It enables selection of higher affinity scFv from a
yeast library generated from error-prone polymerase chain
reaction (PCR) applied to the complete scFv, rather than
focusing on mutation of the CDR loop residues [22]. Using
this method, high antibody affinity can be achieved through
the cumulative effect of many small structural alterations
[23]. This strategy has been successfully used to improve the
affinity and stability of a humanized antibody specific to
carcinoembryonic antigen (CEA) which resulted in improved
retention time into CEA-expressing xenografts [24]. Here,
a similar strategy was used to improve the affinity of an
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Fig. 1 Parental hu1G8 (P) and affinity variant minibodies A2, A11,
and C5. a Sequence of CDRs affected by residue substitution(s). b
Schematic presentations of minibodies and scFv fragments. *Random
residue substitution, VL variable light, VH variable heavy, CH constant
heavy
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anti-PSCA scFv fragment. Three minibody variants demon-
strating higher affinity to PSCA were derived. Furthermore,
to evaluate the potential utility of these affinity variants for
imaging, the minibodies were radiolabeled with 124I for in
vivo microPET imaging studies in two xenograft models:
LAPC-9 (prostate cancer) and Capan-1 (pancreatic cancer).
Materials and methods
Cell lines, antibodies
Yeast strain EBY100 (GAL1-AGA1::URA3 ura3-52 trp1
leu2Δ1 his3Δ200 pep4:HIS2 prb1Δ1.6R can1 GAL) was
grown in YPD medium, EBY100 transfected with expression
vector pYD2 was selected on SD-CAAmedium [25]. Hybrid-
oma and mouse myeloma cells NS0 (ATCC, Manassas, VA,
USA) were grown in Iscove’s modified Dulbecco’s medium
with 5% fetal bovine serum (FBS). The prostate cancer
LAPC-9 was isolated and maintained as previously described
[26]. Capan-1 was obtained from ATCC. The B-cell
lymphoma SKW6.4 and the PSCA-transduced SKW 6.4
cell lines were used to determine the immunoreactive
fraction. They were maintained as previously described
[14]. R-phycoerythrin (PE) AffiniPure F(ab′)2 anti-human or
anti-mouse IgG antibody (Jackson ImmunoResearch Labo-
ratories, West Grove, PA, USA) were used for flow
cytometry detection. Alkaline phosphatase (AP)-conjugated
streptavidin (Jackson ImmunoResearch Laboratories) was
used for enzyme-linked immunosorbent assay (ELISA)
detection. PSCA level of cell surface expression was
determined using QIFIKIT (Dako North America Inc.,
Carpinteria, CA, USA).
Construction of mutant scFv yeast display library
The coding sequences of the VL and VH were extracted
from the parental anti-PSCA huIG8 minibody, fused with
an 18 residue GlySer-rich linker to form scFv in the VL-VH
orientation [14, 27], and cloned into pYD2 expression
vector at NcoI and NotI restriction sites. Random mutations
were introduced into huIG8 scFv by error-prone PCR to
construct a library of huIG8 scFv variants displayed on
yeast surface as previously described [28]. Briefly, the anti-
PSCA huIG8 scFv gene in the pYD2 expression vector was
subjected to 20 cycles of PCR with Taq (Sigma-Aldrich
Corporation, St. Louis, MO, USA) in a reaction mixture
containing 0.5 mM MnCl2. The mutated scFv gene was re-
amplified using a high-fidelity DNA polymerase for 35
cycles. Both PCR reactions used primers Gap5′ and Gap3′
[28]. The PCR product was electrophoresed on an agarose
gel and purified using QIAquick gel extraction (Qiagen,
Chatsworth, CA, USA). The mutated gene mixture was used
to transform lithium acetate-treated EBY100 cells with NcoI/
NotI-digested pYD2 vector, using the TRAFO method with
gap repair [29]. Transformation mixes were cultured and
sub-cultured in SD-CAA media (Current Protocols in
Molecular Biology, Chap. 13). The library size was
determined by plating serial dilutions of the transformation
mixture on SD-CAA plates.
Selection of mutant scFvs yeast display library
The transformed culture was induced in SG-CAA medium
(SD-CAA medium with glucose replaced by galactose) for
24 h at 20°C to express and display scFv on the surface
of yeast. For the first round of selection, 2×107 yeast
(more than 30 times the library size) were washed,
resuspended in FACS buffer [phosphate-buffered saline
(pH 7.4), 0.5% bovine serum albumin] containing 200 nM
of PSCA fused to the human IgG1-Fc domain (PSCA-γ1Fc),
and incubated for 1 h at room temperature. The concentrations
of PSCA-γ1Fc used for rounds 2, 3, and 4 of sorting were 5, 2,
and 1 nM, respectively. After incubation, cells were washed
three times with ice-cold FACS buffer, resuspended in a
1:400 (v/v) dilution of 1 mg/ml SV5-Alexa647 and 1:500
(v/v) dilution of 1 mg/ml anti-human (Fc specific)-PE
conjugate, and incubated for 30 min at 4°C. Before sorting,
the stained cells were washed three times with FACS buffer,
resuspended in 100 μl of FACS buffer, and sorted on a
FACSAria (Becton Dickinson, San Jose, CA, USA). Typically
0.5–1% of the PSCA binding population was gated for
collection under the yield mode for the first two rounds and
the purity mode for the last two rounds. The collected cells
were grown in SD-CAA media and used for the next round of
sorting after induction in SG-CAA. Twenty yeast clones
picked from the fourth round of sorting were analyzed for
comparing the binding activity to the parental scFv by flow
cytometry.
Cloning, expression, and selection of minibodies
To construct the minibodies, the scFv genes were each
fused to a signal peptide upstream, and the human IgG1
hinge and CH3 region downstream [27]. Two million mouse
myeloma cells were transfected with 10 µg of linearized
(cut with Pvu II) plasmid DNA carrying the minibody
construct by electroporation and selected in glutamine-
deficient media. Clones were screened for expression by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blot analysis. Supernatants of
individual clones were electrophoresed on SDS-PAGE and
transferred onto a nitrocellulose membrane for detection
with an anti-human Fc alkaline phosphatase-conjugated
antibody. The strength of the signals was compared and the
highest producing clones were expanded.
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Protein purification and characterization
Soluble minibodies were purified from cell culture super-
natants by protein L chromatography (Poros 50 L, Applied
Biosystems, Foster City, CA, USA) using an ÄKTA
Purifier (GE Healthcare, Piscataway, NJ, USA). The protein
was eluted using 0.1 M glycine pH 2.5 and immediately
neutralized by 2 M Tris-HCl, pH 8 (10% v/v). The purified
proteins were then dialyzed against phosphate-buffered
saline (PBS) and concentrated with a Vivascience Vivaspin
20 (MWCO: 30,000). Final protein concentrations were
determined by measuring UV absorbance at 280 nm (absor-
bance coefficient: 1.67). Purified proteins were analyzed by
SDS-PAGE under non-reducing conditions. Native structural
size was determined by size exclusion chromatography
(Superdex G75, GE Healthcare).
Binding assays
The apparent affinity of intact antibodies for cells expressing
PSCAwas measured as previously described [28]. Briefly, a
range of concentrations of intact antibody were incubated
overnight at 4°C with 5×104 SKW 6.4-PSCA cells. Cell-
bound antibodies were then detected with PE-conjugated
anti-human or anti-mouse IgG antibody. Staining was
analyzed by flow cytometry, and the median fluorescence
intensity (MFI) was determined using the CellQuest software
(Becton Dickinson). To determine the KD, MFI values were
fitted to the equation: MFI ¼ MFIminþMFImax Ab½ =ð
KD þ Ab½ Þ. For standard flow cytometry analysis, 5×105
cells were incubated for 30 min on ice with 100 µl of
minibody at a 2 µg/ml concentration. Cells were washed and
stained with a PE-conjugated goat-anti-human IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA). Com-
petition ELISA assays were performed as previously de-
scribed [13]. ELISA microtiter plates were coated overnight
with 0.5 µg/ml of PSCA-mγ2a recombinant protein. A fixed
amount of biotinylated parental minibody (0.3 nM) wasmixed
with non-biotinylated minibody competitor (parental, A2,
A11, or C5) at a concentration ranging from 0.1 to 200 nM.
Signal was monitored with AP-conjugated streptavidin.
Phosphatase substrate tablets (Sigma-Aldrich Corporation)
were dissolved in diethanolamine buffer to develop the assay.
Assays were carried out in triplicate.
Radioiodination
Purified minibodies were radioiodinated using the iodogen
method with the positron emitting isotope 124I (sodium iodide
in 0.02 M NaOH) provided by IBA Molecular (Sterling, VA)
as previously described [30]. The immunoreactive fraction
was assayed by incubating the same amount of radio-
iodinated minibody with an excess amount of SKW6.4-
PSCA or SKW6.4 cells or no cells for 1 h at room
temperature in the same volume. Approximately 0.2 µCi
(0.03 µg) of radiolabeled minibody was incubated with 20
million cells or no cells in 1 ml PBS/1% FBS. After
incubation cells were pelleted by centrifugation and 0.7 ml of
supernatant was counted in a Wallac WIZARD Automatic
Gamma Counter (PerkinElmer Life and Analytical Sciences
Inc., Boston, MA, USA). The specific immunoreactive
fraction, which is the fraction that binds to the positive cells
(SKW6.4-PSCA), was compared to the negative cells
(SKW6.4). Experiments were carried out in duplicate.
MicroPET/CT imaging and biodistribution studies
All animal studies were conducted under protocols approved
by the Chancellor’s Animal Research Committee at the
University of California, Los Angeles. LAPC-9 xenografts
were established in 7- to 8-week-oldmale SCIDmice (Charles
River Laboratories, Wilmington, MA, USA) by s.c. inocu-
lation of 1×106 LAPC-9 cells near the shoulder blade as
described previously [13]. Capan-1 xenografts were estab-
lished following the same protocol as described above except
that 7- to 8-week-old male nude mice were injected near the
hip. Mice were imaged when tumor masses were in the range
of 100–300 mg. Thyroid uptake of radioiodine was blocked
by adding 10 drops of Lugol (Sigma-Aldrich Corporation)
per 100 ml of drinking water 24 h before injection of
radioiodinated protein. In order to block stomach uptake,
1.5 mg of potassium perchlorate in 0.2 ml of PBS was
administered by gastric lavage 30 min before injection. Each
mouse was injected into the tail vein with 97–207 µCi of 124I
minibody (30–50 µg of protein). Mice were serially imaged
using a Focus 220 microPET scanner (Siemens Preclinical
Solutions, Knoxville, TN, USA). To enable imaging, mice
were anesthetized using 2% isoflurane, positioned in a prone
position along the long axis of the microPET scanner, and
imaged. Acquisition time was 10 min (one bed position), and
images were reconstructed using a filtered backprojection
(FBP) reconstruction algorithm. Directly after the final
microPET scan a CT scan was performed using a microCAT
II (Concorde Microsystems, Knoxville, TN, USA) for
10 min as described [31]. After the final CT scan, mice
were euthanized and tumors, liver, spleen, kidney, lung, and
blood were harvested, weighed, and counted in a Wallac
WIZARD Automatic Gamma Counter (PerkinElmer Life
and Analytical Sciences Inc., Boston, MA, USA). Results
were calculated as percentage of injected dose per gram (%
ID/g) of tissue.
MicroPET analysis
Cylindrical regions of interest (ROI) were drawn from
three-dimensional FBP reconstructed PET/CT coregistered
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images using AMIDE as previously described [32]. From
sagittal images, four ROIs were drawnwithin the tumor in high
activity areas. From the coronal orientation, four ROIs were
drawn in the arm muscle region in the low activity areas close
to the tumors but not directly adjacent to the tumors and termed
“background.” The appropriate positioning of ROIs was
verified looking at each of the three orientations PET/CT
images. Quantitative data were compared for significance
using a one-tailed Student’s t test. All significance testing was
determined at the p<0.05 confidence level. Statistical analysis
was performed using Excel 2000 (Microsoft, Redmond,
WA, USA).
Results
Affinity maturation
In order to improve the affinity of hu1G8, random
mutations were introduced into the hu1G8 scFv gene using
error-prone PCR. The resulting gene repertoire was cloned
into pYD2 that enables expression of scFv variants at the
cell surface of yeasts. A yeast display library of 5.9×105
transformants was created. The library generated was
subjected to four rounds of equilibrium-based selection
using decreasing concentrations of purified recombinant
PSCA protein. Twenty yeast clones from the fourth round
of cell sorting were analyzed by flow cytometry. Eight of
these clones showing strong staining by flow cytometry
were selected and their scFv sequenced. When compared to
the parental scFv sequence A2 DNA sequences were
identical to five other clones with ten mutations, A11 had
six mutations, and C5 had five mutations. These mutations
translated into six, five, and four amino acid substitutions
for A2, A11, and C5 scFv protein sequences, respectively.
Two CDRs, namely VL CDR3 and VH CDR2, were
affected by amino acid substitutions (Fig. 1a). In VL
CDR3, at the same location, a serine was replaced by a
glycine for both the A2 and A11 clones. In VH CDR2, an
asparagine was replaced by a tyrosine and a threonine was
replaced by a serine for the A2 clone. Introduction of a
tyrosine could be more important as they are targeted by
iodination. When compared to the parental scFv, two clones
had a change in the number of tyrosine. In addition to the
A2 clone that had an additional tyrosine introduced into VH
CDR2, the A11 clone had an additional tyrosine introduced
into its framework.
Biochemical characterization of the minibody variants
The parental minibody gene was used as a backbone to
generate three minibody affinity variants by replacing the
scFv insert with each of the three scFv affinity variants: A2,
A11, and C5 (Fig. 1b). The A2, A11, C5, and parental
minibody expression yield levels ranged from ∼6 to 20mg/l of
terminal culture. Minibodies were purified by protein L
chromatography and analyzed on SDS-PAGE (Fig. 2a). The
A2, A11, C5, and parental minibodies migrated as molecular
weight species corresponding to an ∼80 kDa covalently
linked minibody [14]. More significant for this study, SDS-
PAGE analysis also showed that the four purified minibody
variants had similar size and purity. The A11 minibody
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Fig. 2 Biological characterization. a SDS-PAGE analysis in non-
reducing conditions of the four minibodies purified by protein L
chromatography: parental (P), A11, A2, and C5. lane-M, molecular
weight marker. b Size exclusion chromatography profile of A11
minibody purified by protein L chromatography on calibrated Super-
dex 200 Column. c A11 minibody stability; 1 mg/ml stock solution
was stored at −20°C in 20% glycerol, or incubated at 4°C in PBS or
37°C in PBS/5% FBS for 5 days. Binding activity was determined by
ELISA. Each dilution from 3,200 to 12,800 was assayed in triplicate
Eur J Nucl Med Mol Imaging (2010) 37:1529–1538 1533
variant which has been selected for an exploratory imaging
clinical trial was subsequently the subject of extended protein
expression development, stability assays, and further protein
characterization. The best yield obtained for one A11 mini-
body clone was 30 mg/l when expanded to terminal cultures
into 2% FBS, as determined by ELISA (data not shown). The
purified A11 minibody eluted at ∼29 min (Fig. 2b), the same
time as the parental minibody on a size exclusion chroma-
tography [14]. Five-day stability experiments at 4°C in PBS
and at 37°C in 5% FBS demonstrated a 12 and 13% decrease
in activity, respectively, compared to frozen sample (Fig. 2c).
Affinity ranking
Competition ELISA demonstrated that all three minibody
variants had higher affinity than the parental hu1G8 minibody
(Fig. 3a). The apparent affinity as measured by competition
ELISA was estimated to be 11, 16, and 26 nM for A2, A11,
and C5, respectively, compared to 50 nM for the parental
minibody. However, none of the minibodies was able to
compete as well as the mouse monoclonal antibody 1G8.
The four minibodies were also evaluated for their ability to
bind to PSCA-expressing cells by flow cytometry (Fig. 3b).
Flow cytometry data resulted in the same ranking as for the
competition ELISA targeting recombinant PSCA. In conclu-
sion, the apparent affinity of A2 minibody to cell surface
PSCA was the strongest closely followed by A11, then C5
with the parental minibody showing the weakest affinity to
PSCA: A2>A11>C5>parental.
Evaluation of the minibody variants for microPET imaging
of LAPC-9 xenografts
The parental hu1G8minibody labeled with 124I has previously
been evaluated for microPET imaging of a variety of prostate
cancer xenograft models [14]. SCID mice bearing LAPC-9
tumors is a model for which we previously demonstrated
specific tumor targeting of minibody, as an irrelevant mini-
body of the same isotype labeled with 124I did not localize to
the xenograft [14]. We used this model to initially evaluate
the affinity matured minibodies for microPET imaging
efficiency. The A2, A11, and C5 minibodies were all purified
by identical procedure. On the same day, each minibody
affinity variant labeled with the same 124I batch was injected
intravenously into mice bearing PSCA-expressing tumors. In
this experiment radiolabeling was consistent among the three
variants at 88.6% (±1.5%). However, A11 showed better
immunoreactive fraction (60.2%) compared to C5 (49.3%)
and A2 (43.9%). The best images obtained for each affinity
matured minibody are shown in Fig. 4a. The A11 minibody
exhibited the best biodistribution and imaging results with a
tumor to blood ratio of 1.1 and a tumor to background ratio of
4.8 (Fig. 4b). In subsequent studies, A11 was then compared
directly to the parental minibody. Labeling efficiencies and
immunoreactivities of the parental and A11 minibody were
determined after labeling with different batches of 124I. The
labeling efficiencies for parental and A11 minibodies were
89.9% (±2.7; n=4) and 86.6% (±4; n=4), respectively
(Fig. 5). However, the immunoreactive fraction of the A11
minibody was 66% (±6; n=4) and statistically better (p<0.05)
than the immunoreactive fraction of the parental minibody
[45% (±14; n=4)]. Comparison of biodistribution studies
between the two minibodies showed similar tumor uptake for
parental and A11 minibodies at 21 h (3.9%ID/g). However, a
difference between A11 and the parental minibody was
observed when tumor was compared to background values,
i.e., blood activity in the biodistribution, and soft tissue
activity in the images. The A11 minibody demonstrated
overall better biodistribution and imaging results than the
parental hu1G8 minibody in the LAPC-9 model with a tumor
to blood ratio of 1.1 vs 0.8 and a tumor to background ratio
of 5.7 vs 2.4 (Table 1). In conclusion, the tumor image
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Fig. 3 Affinity ranking. a By competitive ELISA binding assay. Plates
were coated with PSCA-mγ2a recombinant protein and biotinylated
parental minibody was used as probe and mixed with different
concentrations of non-labeled competitor: intact monoclonal antibody
1G8, minibody: parental (P), A2, A11, and C5. b By flow cytometry
50 nM of each minibody was incubated with PSCA-expressing cells.
Cells were then stained with anti-human Fc PE-conjugated antibody.
Negative control, A2, A11, C5, and P minibody as are indicated
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contrast was more than twofold better with A11 than parental
minibody in this experiment.
Evaluation of A11 for microPET imaging
of Capan-1 xenografts
A11 was also compared to the parental minibody for targeting
and imaging of PSCA-expressing tumors in a second model:
nude mice carrying Capan-1 xenografts (human pancreatic
cancer). We determined that the Capan-1 cells express ∼30,000
PSCA molecules on their cell surface using QIFIKIT. The
labeling efficiency was again very similar for the parental
hu1G8 (88.4%) and A11 (84.7%) minibodies for this experi-
ment. The immunoreactive fraction was 48.9% for the parental
minibody and 68.4% for the A11 minibody. We obtained
similar imaging contrast with the A11minibody in both LAPC-
9 and Capan-1 models at 21 h with tumor to background ratios
of 4.8 in the LAPC-9 model and 4.2 in the Capan-1 model.
Although the tumor uptakes in the Capan-1 model at 21 h of
both parental and A11 were similar, A11 exhibited a slightly
better tumor to blood ratio than the parental minibody (Fig. 6).
ROI analysis resulted in a tumor to background ratio of 2.2 and
4.2 (n=5, p<0.001) for parental hu1G8 and A11 minibody,
Fig. 5 Labeling of the parental and A11 minibodies. Labeling
efficiency and immunoreactivity were determined for each minibody
(n=4). *The difference between the parental (P) (grey bars) and A11
(black bars) minibodies immunoreactivity was significant (p<0.05)
Table 1 Biodistribution (%ID/g ± SE) and uptake ratios of 124I-
labeled parental (P) and A11 minibodies at 27 h in mice (n=3) bearing
LAPC-9AD tumors
Organ P A11
Tumor 3.9±0.26 3.8±0.95
Blood 4.9±0.56 3.4±0.28
Liver 1.3±0.41 0.8±0.04
Spleen 0.8±0.33 0.7±0.2
Kidney 1.9±0.41 1.3±0.02
Ratio
Tu/Bl 0.8±0.08 1.1±0.15
Tu/Ba 2.4±0.24 5.7±0.56
Tu/Bl (tumor/blood) and imaging data (Tu/Ba, tumor/background)
C5A2 A11
21 h21 h 21 hHigh
Low
Organ A2(n=4)
A11
(n=4)
C5
(n=3)
Tumor 3.7 +/-0.22 6.4 +/-0.91 3.8 +/-0.27
Blood 5.5 +/-0.32 5.9 +/-0.21 5.2 +/-0.41
Liver 1.3 +/-0.14 1.7 +/-0.27 1.5 +/-0.16
Spleen 1.1 +/-0.18 1.4 +/-0.32 1.5 +/-0.32
Kidney 1.9 +/-0.06 2.8 +/-0.36 2.3 +/-0.27
Ratio
Tu/Bl 0.7 +/-0.04 1.1 +/-0.25 0.7 +/-0.04
Tu/Ba 2.2 +/-0.2 4.8 +/-0.8 2.7 +/-0.7
a
b
Fig. 4 In vivo evaluation in
SCID mice bearing LAPC-9
tumors that were injected with
124I-labeled minibodies (A2,
A11, and C5). a Coregistered
microPET/microCT scan of
SCID mice bearing LAPC-9
(PSCA-positive human prostate
cancer) xenografts. The mice
were injected with radiolabeled
minibody variants (A2, A11,
and C5) and scanned at 21 h
post-injection. Coronal
projections are presented
that are adjusted to the same
scale. b Biodistribution, Tu/Bl
(tumor/blood) and imaging data
Tu/Ba (tumor/background) at
21 h post-injection. Tumor and
normal organ uptakes are
expressed as percent injected
dose per gram (%ID/g ± SE)
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respectively. Thus, 124I-labeled A11 minibody was a signifi-
cantly better microPET probe for imaging PSCA-expressing
Capan-1 tumors compared to the parental minibody.
Discussion
We previously demonstrated specific detection of PSCA-
expressing xenografts with the parental hu1G8 minibody at
21 h using microPET imaging [14]. Here, we describe how
affinity variant minibodies were generated and a better
microPET probe was selected. Molecular evolution and
yeast display technology was used to generate three affinity
matured scFvs: A2, A11, and C5 that translated into three
minibodies with better apparent affinity than the parental
minibody. The in vivo evaluation resulted in the selection
of A11 as the best affinity variant to be labeled with 124I to
detect PSCA-expressing xenografts by microPET imaging.
Finally, comparisons of A11 with the parental minibody in
two different xenograft models showed that the A11 affinity
matured minibody resulted in a tumor to soft tissue contrast
twofold higher than what was obtained with the parental
minibody.
The three minibody variants generated, A2, A11, and C5
when analyzed by competition ELISA, all demonstrate
apparent affinity improvement on the parental minibody.
Thus, in these three cases the selection of affinity matured
scFv using yeast display technology translated into
corresponding minibodies with improved affinity. In addition,
the competition ELISA results show that A2, A11, and C5
were able to compete with the parental minibody which
suggests that they all recognize the same epitope on PSCA as
the parental minibody. In conclusion we have generated four
minibodies: A2, A11, C5, and P that recognize the same
epitope on PSCA with apparent affinity measured at 11, 16,
26, and 50 nM, respectively.
The effect of radioiodination of minibody on PSCA
binding was evaluated using SKW6.4 and SKW6.4-PSCA
cells. With consistent labeling efficiency ∼88% from one
124I batch to the next for both the parental and A11
minibodies, we observed that the A11 minibody immuno-
reactive fraction 66% (±6; n=4) was statistically better (p<
0.05) than the parental minibody immunoreactive fraction
45% (±14; n=4). Smaller standard deviation values were
obtained when comparing the difference in immunoreac-
tivity for the same two minibodies on the same day with the
same 124I batch. Thus, variations in the 124I batch seem to
affect immunoreactivity.
The biodistribution data in both LAPC-9 and Capan-1
xenograft models only indicate a small improvement in
A11
Mouse 1                 2                        3              4                        5
P
Organ P A11
Tumor 2.03 +/-0.38 2.03 +/-0.24
Blood 2.54 +/-0.27 2.11+/-0.12
Liver 0.50 +/-0.04 0.47 +/-0.03
Spleen 0.69 +/- 0.03 0.61 +/-0.07
Kidney 0.67 +/-0.06 0.69 +/-0.05
Ratio
Tumor/Blood 0.8 0.96
Low
High
a
b
Fig. 6 In vivo evaluation in
nude mice bearing Capan-1
xenografts. a Coregistered
microPET/microCT scan of
ten nude mice bearing Capan-1
(PSCA-positive human
pancreatic cancer) xenografts.
The mice (n=5) were injected
with 124I-radiolabeled minibody
variants: parental (P) minibody
top row, A11 minibody bottom
row. Mice were scanned and
biodistribution performed at
21 h post-injection. Coronal
projections are presented that
are adjusted to the same scale.
b Biodistribution (n=5) and
Tu/Bl (tumor/blood). Tumor
and normal organ uptakes are
expressed as percent injected
dose per gram (%ID/g ± SE)
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tumor to blood ratio (1.3 and 1.2 times, respectively) that
was not significantly different between the parental and
A11 minibodies. Although tumor and blood activities as
well as tumor to blood ratios are important pharmacokinetic
measurements, they are not directly related to imaging
measurements. Here, we measured the contrast between the
tumor and the soft tissue around the tumor to quantify imaging
results. Ratios would bemuch different if the tumor signal was
compared to the strongest background activity such as the
blood (heart) or the bladder, which are visible in the microPET
images presented. However, the comparison between the
parental and A11 minibody in the low PSCA-expressing
Capan-1 xenograft model is more relevant as the sample size
in the same experiment was bigger (n=5) which allows
statistical analysis of smaller variations. In this model we
obtained a tumor to soft tissue ratio of 4.2 for A11 which is
almost twofold higher (p<0.001) than the ratio obtained for
the parental minibody (2.2).
In vivo, the minibody that ranked with the intermediate
apparent affinity (A11) demonstrated best microPET imaging
results, with the best affinity minibody (A2) showing the
worst results. The poor in vivo result of A2 is unlikely a
consequence of higher affinity since the difference between
A2 and A11 KD was determined to be only around 5 nM.
One possible reason for the poor performance of A2 is the
presence of a new tyrosine in the VH CDR2. Iodination of
this tyrosine during labeling might affect binding to PSCA.
Consistent with an effect of iodination with the poor imaging
results obtained for A2 imaging is that the A2 minibody had
the lowest immunoreactivity of the three affinity variants.
However, A2 immunoreactivity was still close to 40%, and
other parameters such as protein stability in vivo could also
be involved. The overall observation is that different affinity
variants with similar apparent affinity exhibited different
microPET imaging properties. Comparison between in vitro
and in vivo characterization of peptide probes to select the
best microPET tracers has recently been carried out [33]. In
this study, 43 peptides were evaluated as microPET tracers to
detect αvβ6-expressing tumors. This in vivo selection
resulted in the selection of four peptides that would not
have been selected on the bases of their in vitro character-
ization including their affinity. Thus, the best strategy to
develop new microPET tracers seems to be the development
of high-throughput technology for the generation and testing
of new protein-based microPET tracers rather than extensive
in vitro studies of many different parameters.
The A11 minibody has been selected for evaluation in a
clinical setting for a number of reasons. We generated clones
that express high yields of minibody that was stable at 37°C.
A11 has higher affinity to PSCA and higher immunoreactivity
after 124I labeling than the parental minibody. Finally, A11
antibody showed highest microPET imaging contrast in two
different xenograft models.
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